Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy.

Trial Profile

Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Brivanib alaninate; Cetuximab
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 22 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top